Assessing the commercial potential of an asset in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Making informed clinical and commercial decisions can help to optimize the value of an asset for pharmaceutical companies. SmartAnalyst was approached with the task of assessing a product in development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the US, EU5, and Japan.
SmartAnalyst was challenged to identify potential market and product-related drivers and quantify which assumptions might be associated with identified drivers. Adopting a two-stage approach, SmartAnalyst looked at the current disease and market landscape before conducting a Quantitative Survey to assess the potential of the asset.
SmartAnalyst generated plausible commercial scenarios based on product attributes and market access considerations to inform product development.
Read the full case study here.
Jump to a slide with the slide dots.
How can AI-powered speech analytics scale call monitoring and improve agent performance?
Discover how Inizio Engage used AI-driven speech analytics to scale call monitoring, enhance agent performance, and improve customer interactions.
Read moreHow DataGateway unified oncology data for real-world insights & market intelligence
A global biopharma company used DataGateway platform to unify complex oncology data into a validated, patient-level dataset - boosting coverage by 80%
Read moreHow can AI-powered call routing transform customer experience and drive operational efficiency?
Discover how an AI-powered Virtual Agent streamlined call routing - reducing manual triage by 50% and enhancing customer experience.
Read more